Phase Ib Clinical Investigation of Intraperitoneal Ipilimumab and Nivolumab in patients with peritoneal carcinomatosis due to gynecologic cancers
MD Anderson Study Status
Ipilimumab + Nivolumab, Nivolumab (Opdivo), Ipilimumab, Nivolumab
This phase Ib trial studies the side effects and best dose of nivolumab with or without ipilimumab in treating patients with female reproductive cancer that has come back (recurrent) or is high grade and has spread extensively throughout the peritoneal cavity (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Information and next steps
Gynecologic Oncology & Reproductive Medicine
For general questions about clinical trials: